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Abstract
AIM
To assess the rate of matrix Gla-protein carboxylation 
in patients with small intestinal bacterial overgrowth 
(SIBO) and to decipher its association with subclinical 
atherosclerosis.
METHODS
Patients with suspected SIBO who presented with a low 
risk for cardiovascular disease and showed no evidence 
of atherosclerotic plaques were included in the study. 
A glucose breath test was performed in order to 
confirm the diagnosis of SIBO and vascular assessment 
was carried out by ultrasound examination. Plasma 
levels of the inactive form of MGP (dephosphorylated-
uncarboxylated matrix Gla-protein) were quantified by 
ELISA and vitamin K2 intake was estimated using a 
food frequency questionnaire.
RESULTS
Thirty-nine patients were included in the study. 
SIBO was confirmed in 12/39 (30.8%) patients 
who also presented with a higher concentration of 
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Subclinical atherosclerosis is linked to small intestinal 
bacterial overgrowth via  vitamin K2-dependent mechanisms
Observational Study
Francesca Romana Ponziani, Maurizio Pompili, Enrico Di Stasio, Maria Assunta Zocco, Antonio Gasbarrini, 
Roberto Flore
dephosphorylated-uncarboxylated matrix Gla-protein 
(9.5 μg/L vs  4.2 μg/L; P  = 0.004). Arterial stiffness was 
elevated in the SIBO group (pulse-wave velocity 10.25 
m/s vs  7.68 m/s; P  = 0.002) and this phenomenon 
was observed to correlate linearly with the levels of 
dephosphorylated-uncarboxylated matrix Gla-protein (β 
= 0.220, R 2 = 0.366, P  = 0.03). Carotid intima-media 
thickness and arterial calcifications were not observed 
to be significantly elevated as compared to controls.
CONCLUSION
SIBO is associated with reduced matrix Gla-protein 
activation as well as arterial stiffening. Both these 
observations are regarded as important indicators of 
subclinical atherosclerosis. Hence, screening for SIBO, 
intestinal decontamination and supplementation with 
vitamin K2 has the potential to be incorporated into 
clinical practice as additional preventive measures.
Key words: Small intestinal bacterial overgrowth; 
vitamin K; Dysbiosis; Atherosclerosis; Cardiovascular 
disease risk
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The matrix Gla-protein is involved in 
maintaining vascular health and vitamin K2 is a 
prerequisite for its activation and function. Intestinal 
bacteria are the main source of vitamin K2 in humans 
and small intestinal bacterial overgrowth (SIBO) is 
associated with altered vitamin K2 metabolism. This 
study demonstrates that SIBO is associated with 
increased plasma levels of inactive matrix Gla-protein, 
which, in turn, correlates directly with early markers 
of atherosclerotic disease such as increased arterial 
stiffness. Therefore, SIBO has the potential to serve as 
an indicator for increased risk of developing an overt 
cardiovascular disease.
Ponziani FR, Pompili M, Di Stasio E, Zocco MA, Gasbarrini A, 
Flore R. Subclinical atherosclerosis is linked to small intestinal 
bacterial overgrowth via vitamin K2-dependent mechanisms. 




The presence of bacteria in the gastrointestinal tract 
is crucial for maintaining host health. One of the most 
important functions of gut bacteria is to metabolize 
carbohydrates, lipids, and proteins derived from food 
and to synthesize nutrients that are not adequately 
supplied by the diet.
Vitamin K is a lipophilic vitamin that is present 
in two main forms: (1) phylloquinone or vitamin 
K1; and (2) menaquinone (MK) or vitamin K2; the 
nomenclature is representative of the number of 
prenyl units contained in these isoforms[1]. Studies 
conducted on European populations have shown that 
the bulk of vitamin K intake in Western diets is in the 
form of phylloquinone (90%) with menaquinones 
accounting for only 10% (about 7.5% by MK-5 
through to MK-13 and 2.5% by MK-4)[2]. This can be 
partially accounted for the fact that menaquinones are 
found only in meat, dairy-based foods and fermented 
soybeans (known as “natto”) that are a part of the 
Japanese diet. Therefore, while MK-4 is obtained by 
peripheral tissue conversion of menadione, which is 
produced by intestinal cleavage of phylloquinone[2], 
the bulk of menaquinones is derived from gut bacteria 
biosynthesis. In particular, bacterial species, such as 
Eggerthella lenta and Veillonella, are involved in the 
production of MK-7 while Enterobacteriaceae, such as 
Escherichia coli and Shigella, are responsible for the 
production of MK8. Bacteroides produce MK9-11 and 
Prevotella synthesize MK-5 and MK11-13[2,3]. 
Vitamin K2 is a cofactor that is involved in 
the carboxylation of several proteins, such as the 
matrix Gla-protein (MGP)[4]. The MGP is expressed 
by chondrocytes, vascular smooth muscle cells, 
endothelial cells and fibroblasts, and its primary 
function is to bind calcium crystals present in the vessel 
wall thereby preventing their nucleation on elastin 
fibers. Additionally, MGP also prevents osteoblastic 
differentiation of vascular smooth muscle cells 
and maintains the composition of the extracellular 
matrix[5]. Hence it can be concluded that MGP plays 
a crucial role in maintaining both arterial structure as 
well as function. Increased levels of the inactive form 
of MGP (dephosphorylated-uncarboxylated MGP, dp-
ucMGP) is widely regarded as one of the best marker 
for low vitamin K2 status[6] and has been known 
to be associated with the signs of early vascular 
disease (intima-media thickening, arterial stiffness, 
and vascular calcifications)[7-14] and cardiovascular 
morbidity and mortality[15-17].
Although several recent studies have highlighted 
that patients with small intestinal bacterial overgrowth 
(SIBO) have low circulating levels of vitamin K2[18], 
investigations exploring the clinical relationship 
between SIBO, MGP activity, and arterial structure and 
function are still lacking. 
The aim of this study was to investigate the rate 
of MGP carboxylation in patients with SIBO and to 
decipher its association with the risk of developing 
subclinical atherosclerosis.
MATERIALS AND METHODS
During a six month period, all outpatients at the 
Gastroenterology Division of the Agostino Gemelli 
Hospital in Rome that presented with clinical signs of 
SIBO (e.g., bloating, abdominal pain, and diarrhea) 
were included in the study. 
Patient history with an emphasis on the personal 
1242 February 21, 2017|Volume 23|Issue 7|WJG|www.wjgnet.com
Ponziani FR et al . Atherosclerosis and dysbiosis
and family history of coronary heart disease, lifestyle, 
and pharmacotherapy was stringently recorded. 
Only subjects that were between 40 and 60 
years without any previous cardiovascular events 
(including myocardial infarction or angina, congestive 
heart failure, intermittent claudication, previous 
arterial revascularization, thromboembolic disease 
and stroke) and with a low cardiovascular disease 
risk (as per the Framingham risk score up to 8 
points) were considered eligible for inclusion in this 
investigation[19]. The exclusion criteria were (1) current 
heavy smoking (> 10 cigarettes/d by self-report); 
(2) morbid obesity (body mass index > 30 kg/m2); 
(3) dyslipidemia (LDL cholesterol > 160 mg/dL); (4) 
hypertriglyceridemia (triglycerides > 400 mg/dL); and 
(5) uncontrolled hypertension (systolic blood pressure 
> 140 mmHg and/or diastolic blood pressure > 95 
mmHg). The patients suffering from diabetes, chronic 
kidney disease (at any stage), those receiving oral 
anticoagulant treatment and those afflicted with any 
carotid, aortic, femoral, and popliteal plaque (according 
to the Mannheim criteria as detected at the time of 
ultrasound examination) were also excluded from the 
protocol[20].
The patients fulfilling the selection criteria under-
went a glucose breath test (GBT), filled in a food 
frequency questionnaire for the assessment of daily 
vitamin K2 intake, provided a blood sample for the 
quantification of circulating dp-ucMGP, and underwent 
ultrasound (US) examination of the non-coronary 
arterial system. 
The study was performed in agreement with the 
Declaration of Helsinki and subsequent amendments. 
Written informed consent was obtained from all 
patients.
GBT test for SIBO diagnosis
All patients included in the study underwent a GBT 
to confirm the diagnosis of SIBO[21]. In order to avoid 
false positive or negative results, each patient was 
advised to strictly adhere to certain instructions before 
taking the test. These conditions were (1) laxatives, 
antibiotics, and prokinetics to be prohibited for at 
least four weeks before the GBT; (2) consumption of 
a low-fiber dinner was allowed but the patients were 
prohibited from eating or drinking eight hours before 
the test; (3) washing of mouth with antiseptics was 
done immediately before administration of the test; 
and (4) smoking, chewing gum, and doing physical 
exercise were prohibited before and during the test.
The GBT procedure was performed according to 
the recommendations of the Rome consensus[22]. The 
procedure was as follows: after the administration of 
50 g glucose dissolved in 250 mL of water, hydrogen 
and methane excretion in the expired air was assessed 
at 15-min intervals for a total time period of 120 min. 
These values were then compared to baseline values. 
SIBO diagnosis was regarded as confirmed if the 
expired air exhibited an increase of at least 12 parts 
per million (ppm) above the baseline in hydrogen and/
or methane activity.
Quantification of vitamin K2 daily intake 
In order to assess the daily intake of vitamin K2, a food 
frequency questionnaire obtained from the European 
Prospective Investigation on Cancer and Nutrition 
(EPIC) nutrient database project was readapted and 
used[23]. 
The questionnaire was structured into three 
sections. The first section addressed the type and 
frequency of foods that were consumed by the 
subjects and included a list of more than 100 items 
divided into categories (fruit, vegetables, cereals, 
pasta/bread/rice, soups, meat, fish, eggs, milk/dairy 
products, fast food products, condiments, sweets, 
beverages, and vitamins). The frequency of intake 
of each food item was recorded and ranked (daily, 
weekly, monthly, yearly, or never). 
The second section estimated the serving size and 
ranked it according to food weight (small, medium, 
and large portions). 
Finally, the last section of the questionnaire 
investigated cooking habits (e.g., addition of salt to 
foods, preferred cooking method, etc.). 
For the purpose of the study, scientific literature 
was reviewed in order to identify vitamin K2 rich 
foods that are commonly present in a Western diet. 
The results of the literature survey were taken into 
consideration while composing the food questionnaire 
so as to avoid underestimation of vitamin K2 intake by 
the study subjects. A list of vitamin K2 content in food 
is provided as Supplementary Table 1. 
Although the food frequency questionnaire only 
referred to the dietary intake of the previous 12 mo, all 
subjects participating in the study attested to having 
followed a stable dietary regimen for the last five 
years.
Plasma assay dp-ucMGP 
Citrated plasma was separated from whole blood by 
centrifuging at 1500 × g for 10 min. The aliquots 
of 2 mL each were frozen at -20 ℃ or -80 ℃ within 
30 min of blood sampling. For long-term storage 
exceeding 2 months, all samples were kept at -80 ℃ 
till use. dp-ucMGP concentration was assessed using 
a dual-antibody test based on the sandwich ELISA 
methodology developed by VitaK (inaKtif MGP iSYS 
kit, Immunodiagnostic Systems Ltd, Boldon, United 
Kingdom). 
Ultrasound examination 
The US and Doppler US (D-US) examination of the 
non-coronary arterial system was conducted in order 
to examine for early signs of vascular dysfunction 
(arterial stiffening) and for the presence of early 
vascular lesions (intima-media thickening, arterial 
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parameters. A linear regression was constructed using 
PWV as dependent variable, and the assumptions were 
verified by the appropriate diagnostics. Correlations 
and regression analyses were performed on both 
the overall population as well as the SIBO group 
separately. 
Statistical analysis was conducted using the R 
statistics program version 3.1.2[27]. All statistical tests 
were two-sided and differences were considered 
significant at P-values below 0.05. 
RESULTS
Amongst the 189 patients that were initially recruited 
into the study, 44 were deemed ineligible as a result 
of moderate or high Framingham risk score. A further 
86 were ruled out as they were found to be afflicted 
with one or more of the comorbidities listed among the 
exclusion criteria. Twenty patients refused consent for 
being a part of this investigation (Figure 1). Eventually, 
39 patients were selected to be a part of this study. 
Patient characteristics are described in Table 1. The 
median age of the study group was 53 (41-60) years, 
and 14 (35.9%) of the participants were male. SIBO 
was diagnosed in 12/39 (30.8%) patients and the 27 
patients without SIBO were regarded as the control 
group (no-SIBO group). The analysis of the data 
contained in the food questionnaires revealed that the 
median vitamin K2 daily intake was approximately 
29.5 (8-103.6) μg/d. No differences in median age, 
sex, and Framingham score could be observed 
between the SIBO and no-SIBO groups.
Vitamin K2 intake was determined to be 21.2 
(8-49.7) μg/d in the SIBO group, which was similar 
to 31.9 (10.5-103.6) μg/d consumed by the control 
subjects in the no-SIBO group (P = 0.111). The 
median dp-ucMGP serum level was 4.76 μg/L (1.75–
25.7) (Table 2); dp-ucMGP was observed to be 
significantly increased in patients with SIBO (9.5 μg/L 
vs 4.2 μg/L, P = 0.02; Table 2 and Figure 2).
The daily intake of vitamin K2 was not associated 
with plasma levels of dp-ucMGP (t = -0.08, P = 0.441). 
Sixteen of the 39 patients (41%) presented with at 
least one or more microcalcifications in the explored 
arterial districts (Supplementary Table 2). It is to be 
noted however that no arterial plaque was detected. 
In the overall population, median carotid artery PWV 
was 8.5 m/s (5.69-14) and median IMT was 661 μm 
(467-1009). In patients with SIBO, the median PWV 
was significantly higher than that observed in the no-
SIBO group (10.25 m/s vs 7.68 m/s; P = 0.002; Figure 
3) but the median IMT value and the rate of early 
arterial calcifications did not differ substantially (Table 
2). dp-ucMGP levels correlated with arterial stiffness as 
measured by PWV (t = 0.339, P = 0.002). In particular, 
regression analysis showed that there was a significant 
direct linear correlation between dp-ucMGP and PWV (β 
= 0.219, R2 = 0.293, P = 0.0004; Figure 4).
Additionally, in patients with SIBO, a direct linear 
calcifications, and subclinical plaques).
Arterial stiffness was assessed by applying an 
automated radiofrequency-based method (Quality 
Arterial Stiffness (RF-QAS); Esaote Medical Systems, 
Genova, Italy) to the D-US examination of the left 
common carotid artery. Local pulse-wave velocity 
(PWV) was calculated by combining arterial distension 
with local distending pressure measure. Assuming a 
constant difference between mean arterial pressure 
and diastolic pressure along the arterial tree, the QAS 
system is able to detect systo-diastolic changes in the 
arterial diameter following arterial wall movements 
during the cardiac cycle and to convert local distension 
variations in modifications of local distending pressure 
(pulse pressure). PWV was calculated by the Bramwell-
Hill equation[24,25], as follows: 
PWV = √ΔP · V/ΔV · ρ
where ΔV and ΔP are changes in volume and 
pressure, respectively, and ρ is the density of blood. 
As per the equation, PWV increases when there is an 
increase in arterial stiffness.
Using the same radiofrequency-based technology 
outlined above, intima-media thickness (IMT) was 
measured (Quality Intima-Media Thickness (RF-QIMT); 
Esaote Medical Systems, Genova, Italy) in a 1 cm 
long segment of the left common carotid artery, i.e., 1 
cm before the bifurcation. To preserve measurement 
quality, mean IMT values calculated over 6 cardiac 
cycles were recorded only if the standard error was 
lower than 20 μm. 
The presence of vascular calcifications was 
investigated by B-mode US in 11 vascular segments 
(common carotid arteries, common femoral arteries, 
popliteal arteries, posterior tibial arteries, anterior tibial 
arteries, and subrenal abdominal aorta) as has been 
previously described in the literature[26]. 
Statistical analysis
The Shapiro-Wilk test was performed to verify the 
normality of data distribution and statistical analysis 
was carried out using non-parametric tests. 
Continuous variables were expressed as median 
and range (minimum and maximum value) while 
categorical variables were expressed as frequencies 
and percentages. 
For comparing patients with SIBO with those 
without, the Mann-Whitney and chi-square tests were 
applied in order to highlight differences, if any, in 
baseline characteristics such as sex, age, and vitamin 
K2 intake. The same tests were also employed to test 
discrepancies in variables under study (plasma levels 
of dp-ucMGP, PWV, IMT, vascular calcifications).
Due to the presence of repeat values in the 
dataset, Kendall’s tau-b correlation coefficient was 
used to investigate the association between dp-
ucMGP levels, PWV, IMT, and vascular calcifications. 
Additionally, data distribution was explored in order to 
find the best-fit regression model for elucidating the 
relationship between dp-ucMGP levels and US/D-US 
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correlation between dp-ucMGP levels and PWV could 
be verified (β = 0.220, R2 = 0.366, P = 0.03) but no 
such relation was found between dp-ucMGP and IMT (P 
= 0.507).
In the no-SIBO group, no significant relationship 
between dp-ucMGP, arterial stiffness, and IMT could be 
observed (P = 0.08 and P = 0.415, respectively).
DISCUSSION
In recent years, the studies on identifying early 






















Figure 1  Study workflow.
Table 2  Comparison of circulating levels of dephosphorylated-uncarboxylated matrix Gla-protein and ultrasound parameters (pulse-
wave velocity, intima-media thickness, and vascular calcifications) in patients with or without small intestinal bacterial overgrowth
Overall SIBO (n  = 12) no-SIBO (n  = 27) P  value
dp-ucMGP (μg/L)  4.73 (1.75-23.8) 9.5 (3.6-23.8)    4.2 (1.75-14.5)  0.004a
PWV (m/s) 8.5 (5.7-14) 10.25 (5.7-14) 7.68 (5.6-11)  0.002a
IMT (μm)   661 (467-1009)  596 (467-1009) 663 (506-932) 0.465
Calcifications 16 (41) 6 (50) 10 (37) 0.609
Data are expressed as median (range) or frequency (%), significant comparisons (aP < 0.05). SIBO: Small intestinal bacterial overgrowth; dp-ucMGP: 
Dephosphorylated-uncarboxylated matrix Gla-protein; PWV: Pulse-wave velocity; IMT: Intima-media thickness.
Table 1  Patients’ baseline characteristics
Overall SIBO (n  = 12) no-SIBO (n  = 27) P  value
Age 53 (41-60) 55 (41-60) 57 (43-60) 0.306
Sex (males/females) 14 (35.9)/25 (64.1) 2 (16.7)/10 (83.3) 12 (44.4)/15 (55.6) 0.095
Vitamin K2 intake (μg/d) 29.5 (8-103.6) 21.2 (8-49.7) 31.9 (10.5-103.6) 0.111
Males: 25.7 (8-103.6)
Females 29.6 (10.4-91.8)
Framingham risk score 5.4 (2-8) 5.5 (2-7) 5.2 (2-8) 0.897
Males: 5.8 (2-8)
Females: 6.9 (0-8)
Data are expressed as median (range) or frequency (%). Comparisons have been performed between SIBO and no-SIBO group. Framingham score was built 
on age, sex, race, arterial pressure, smoking, diabetes, total blood cholesterol, HDL-cholesterol. SIBO: Small intestinal bacterial overgrowth.
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amount of scientific interest. The early identification of 
vascular dysfunction and lesions has the potential to 
help individuals that stand to benefit from prevention 
of disease progression policies[28-30]. 
For the successful implementation of strategies 
aimed at prevention of disease formation and 
progression, it is crucial to recognize pathologies 
that function as risk factors for the development of 
atherosclerosis. Several diseases of the gastrointestinal 
tract, wherein gut bacteria act in a pathogenic 
capacity, are associated with vascular dysfunction and 
increase the risk of atherosclerosis in the host[31-33]. 
Nevertheless, it has been recently demonstrated 
that metabolic products generated by gut bacteria 
are implicated in the development of atherosclerotic 
lesions[34].
MGP is a vitamin K2 dependent protein that helps 
in preventing calcium accumulation in the arterial 
wall. Humans need gut bacteria in order to fulfill 
their vitamin K2 requirement as dietary intake is 
often insufficient. This is especially true in the case 
of the Western population. SIBO, a condition that is 
characterized by gut bacteria dysbiosis, is associated 
with impaired vitamin K metabolism in humans[18,35]. 
For this reason, patients afflicted with SIBO and/or 
low vitamin K2 status could hypothetically be at an 
increased risk for the development of atherosclerotic 
disease. 
To the best of our knowledge, the present study is 
the first to investigate the consequences of vitamin K2 
metabolism derangement on MGP activity in patients 
with SIBO. When compared to the control group, 
the SIBO group presented with higher dp-ucMGP 
serum levels, which is suggestive of either a reduced 
dietary vitamin K2 intake or an altered vitamin K2 
production by intestinal bacteria. It is to be noted 
that the daily median vitamin K2 intake of patients 
included in the study was comparable to that of other 
European populations[36,37] and was similar between 
patients with SIBO and those without (21.1 μg/d vs 
31.9 μg/d, P = 0.111; Table 2). As plasma vitamin 
K2 levels are difficult to assess with accuracy[38], we 
adopted dp-ucMGP levels as surrogate biomarkers 
for estimating the vitamin K2 nutritional status. Our 
results strongly indicated that dietary vitamin K2 
intake does not correlate with dp-ucMGP serum levels. 
This observation indirectly confirms the previously 
reported theory that food is not the primary source 
of vitamin K2 supplementation in humans and that 
the gut microbiota is crucial for overcoming dietary 
insufficiencies under physiologic conditions[2,3].
In all subjects including those in the SIBO group, 
the serum levels of inactive dp-ucMGP were found 
to directly correlate with PWV, which is a surrogate 
parameter of arterial stiffness. However, no significant 
association was found with either IMT or the presence 
of calcifications. Atherosclerosis is a progressive 
Figure 2  Plasma concentration of dephosphorylated-uncarboxylated 
matrix Gla-protein in patients under study. Patients with small intestinal 
bacterial overgrowth (SIBO) exhibited significantly higher levels as compared 
to the patients without SIBO (9.5 μg/L vs 4.2 μg/L; P = 0.02). Median values 
are represented by boxplot internal lines and ranges by whiskers. dp-ucMGP: 
Dephosphorylated-uncarboxylated matrix Gla-protein.
Figure 3  Pulse-wave velocity values observed in the study population. 
Pulse-wave velocity (PWV) was increased in patients with small intestinal 
bacterial overgrowth (SIBO) compared to the no-SIBO group (10.25 m/s vs 7.68 
m/s; P = 0.002). Median values are represented by boxplot internal lines and 
ranges by whiskers.
Figure 4  Linear regression model highlighting the direct correlation 
between plasma concentration of dephosphorylated-uncarboxylated 
matrix Gla-protein and pulse-wave velocity (β = 0.219, R2 = 0.293, P = 
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disease characterized by a wide spectrum of vascular 
changes[39]. While arterial stiffening is an early marker 
of vascular dysfunction, intima-media thickening and 
calcifications are the first structural changes that 
can be detected in atherosclerotic vessels; these 
changes are usually a manifestation of the adaptive 
remodeling to flow, wall tension, and lumen diameter 
alterations[40]. As a result of this, even in the cases 
that are potentially at low risk for the development 
of cardiovascular diseases, SIBO appears to cause 
early vascular dysfunction possibly due to reduced 
MGP activity. This observation holds true even in 
the absence of clear signs of structural alterations. 
The absence of a statistical correlation between dp-
ucMGP values and initial signs of vascular remodeling 
can be explained by the absence of study subjects 
with medium and high Framingham risk scores. It 
is reasonable to argue that in the presence of other 
cardiovascular risk factors, patients with SIBO may 
be at increased risk for developing structural arterial 
lesions as compared to patients without SIBO, and that 
SIBO itself may confer an increased risk of developing 
an overt cardiovascular disease. Therefore, based on 
the results obtained in our study, we propose that even 
asymptomatic patients should be screened for SIBO 
so as to rule out an additional factor that predisposes 
patients to cardiovascular diseases. This screening 
is especially important for patients with known 
atherosclerotic lesions or previous cardiovascular 
events as it offers a chance for therapeutic intervention 
so as to correct a condition that can potentially 
contribute to disease progression. In patients with 
SIBO vitamin K2 supplementation and intestinal 
decontamination, along with additional preventive 
measures, may be therefore recommended.
The present study suffers from certain limitations. 
Firstly, information regarding the specific composition 
of the small intestinal bacteria was not collected due 
to the invasiveness of the procedure. In addition, 
at our institution, SIBO is diagnosed by GBT as 
per the Rome consensus recommendations[18]. We 
were, therefore, unable to perform metagenomic or 
metabolomic analyses to assess if the abundance of 
bacteria specifically involved those involved in vitamin 
K2 production.
Secondly, instead of computed tomography 
(CT) scans, US and D-US were used to investigate 
the presence of vascular calcifications and flow 
parameters. This was done because US is less harmful, 
easily reproducible and allows for the quantification 
of parameters useful for assessing arterial stiffness 
whereas CT scans require radiation exposure and are 
also more expensive[41]. 
Lastly, this study included a relatively small 
number of patients. A strict adherence to the selection 
criterion was followed so as to avoid the effect of 
confounding factors such as treatment with oral 
vitamin K antagonists, diabetes and kidney disease 
on MGP carboxylation, or the influence of the previous 
history of vascular disease and of moderate/high 
cardiovascular disease risk on the prevalence of 
vascular calcifications and on the measurement of 
D-US parameters. The exclusion of patients with 
comorbidities limited external interactions which 
allowed us to exclusively evaluate the correlation 
between SIBO, vitamin K2 metabolism, MGP 
carboxylation and early arterial dysfunction or vascular 
lesions without the interference of any confounding 
factors.
In conclusion, patients affected by SIBO have 
higher levels of inactive MGP as well as increased 
arterial stiffness both of which are early markers for 
vascular dysfunction. This condition is not influenced 
by vitamin K2 intake from diet confirming that bacteria 
are the main source of this vitamin in humans and 
that vitamin K2 metabolism may be altered as a 
consequence of small intestinal dysbiosis. Longitudinal 
studies assessing the role of SIBO as a condition 
that predisposes patients to the development of 
atherosclerosis are needed; for this category of 
patients, vitamin K2 supplementation and the 
treatment of intestinal dysbiosis may be therapeutic 
alternatives of significant utility.
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